Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Sino Biopharmaceutical Expands GSK Partnership to Commercialize Trelegy and Anoro Ellipta in China

Fineline Cube Jul 8, 2026
Company Deals

Immunocon, MabGalaxy Forge Full-Chain AI Antibody R&D Network for Bispecific Drug Development

Fineline Cube Jul 7, 2026
Company Deals

Vertex Pharmaceuticals to Acquire Crinetics for $10B, Adding PALSONIFY and Atumelnant to Endocrine Portfolio

Fineline Cube Jul 7, 2026
Company Deals

Hainan Shuangcheng Pharmaceutical Secures $10M US Licensing Deal for SC-C141 R&D Project

Fineline Cube Jul 7, 2026
Company Deals

CStone Pharmaceuticals Partners with Arrotex for Sugemalimab Commercialization Across Australia and New Zealand

Fineline Cube Jul 7, 2026
Policy / Regulatory

China Adds Methoxyethyl Etomidate, Loretomidate and Solriamfetol to Controlled Psychotropic Substances List

Fineline Cube Jul 8, 2026
Company Drug

Shanghai Stexo Biotechnology Secures NMPA Clinical Approval for STX11101 Extracellular Vesicle Therapy in Acute Liver Failure

Fineline Cube Jul 8, 2026
Drug Policy / Regulatory

China NMPA Launches PIONEER Program to Accelerate NAMs Adoption in Drug Development

Fineline Cube Jul 7, 2026
Company Drug

Zhongsheng Pharma’s Onradivir Granted Drug Registration in Macau

Fineline Cube Aug 22, 2025

Guangdong Zhongsheng Pharmaceutical Co., Ltd. (SHE: 002317) announced that its onradivir tablets have received a...

Company Deals

Tianjin Lisheng Plans RMB 1 Billion Fund with Strategic Partners

Fineline Cube Aug 22, 2025

Tianjin Lisheng Pharmaceutical Co., Ltd. (SHE: 002393), based in China, announced plans to co-establish the...

Company

Hengrui Pharmaceuticals Reports 15.88% Revenue Growth in 2025 Semi-Annual Results

Fineline Cube Aug 22, 2025

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (HKG: 1276, SHA: 600276) has released its 2025 semi-annual report, highlighting...

Policy / Regulatory

China’s NMPA Resumes Import of Vasudha’s Loratadine API After Rectifications

Fineline Cube Aug 22, 2025

China’s National Medical Products Administration (NMPA) announced on August 20, 2025, that it had resumed...

Company Deals Drug

Jazz Pharmaceuticals Secures Global Rights to Saniona’s Epilepsy Drug SAN2355

Fineline Cube Aug 22, 2025

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) and Saniona (STO: SANION) announced today that they have entered...

Company Deals

Kite Pharma Acquires Interius BioTherapeutics for $350 Million to Boost CAR Therapy Platform

Fineline Cube Aug 22, 2025

On August 22, 2025, Kite Pharma, Inc., a subsidiary of Gilead Sciences (NASDAQ: GILD), announced...

Company Drug

Ionis Pharmaceuticals’ DAWNZERA Approved by FDA for HAE Prevention

Fineline Cube Aug 22, 2025

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced on August 22, 2025, that the U.S. Food and...

Company Drug Policy / Regulatory

InnoCare Pharma’s ICP-723 Joins China’s SPARK Project for Pediatric Solid Tumors

Fineline Cube Aug 22, 2025

China’s Center for Drug Evaluation (CDE) under the National Medical Products Administration (NMPA) has announced...

Company Medical Device

Lifetech Scientific’s PDA Occluder Gains NMPA Innovative Device Review Status

Fineline Cube Aug 22, 2025

On August 22, 2025, China-based Lifetech Scientific Corporation (HKG: 1302) announced that its nitinol patent...

Company Deals

Bio-Thera Inks EUR 136m Deal with STADA for BAT1806 Commercialization

Fineline Cube Aug 21, 2025

On August 21, 2025, Bio-Thera Solutions, Ltd. (SHA: 688177) announced a license and commercialization agreement...

Company Deals

3D Medicines and CATUG Biotech Forge Strategic Alliance in mRNA-LNP Innovation

Fineline Cube Aug 21, 2025

China-based 3D Medicines (HKG: 1244) has entered into a strategic cooperation framework agreement with CATUG Biotechnology....

Company Drug

Bio-Thera Adjusts BAT3306 Clinical Study to Meet Regulatory Standards

Fineline Cube Aug 21, 2025

On August 21, 2025, China-based Bio-Thera Solutions, Ltd. (SHA: 688177) announced a strategic adjustment to...

Company Drug

Novartis’ Atrasentan Approved in China for IgAN Proteinuria Reduction

Fineline Cube Aug 21, 2025

Switzerland-based Novartis (NYSE: NVS) has received approval from China’s National Medical Products Administration (NMPA) for...

Company Drug

Suzhou Zelgen’s ZG005 and Gecacitinib Win NMPA Approval for Advanced Solid Tumors

Fineline Cube Aug 21, 2025

On August 21, 2025, Suzhou Zelgen Biopharmaceuticals Co., Ltd. (SHA: 688266), a China-based company, announced...

Others

Minova’s MI078 Shows Promising Results in Postpartum Depression Trial

Fineline Cube Aug 21, 2025

Nanjing-based Minova Pharmaceuticals Co., Ltd. has announced positive results from a Phase 2 clinical trial...

Company Deals

Abbisko’s ABSK043 Gains IND Approval for KRAS G12C NSCLC in Partnership with Allist

Fineline Cube Aug 21, 2025

Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) announced that the Center for Drug Evaluation...

Company Drug

Sino Biopharma’s Zongertinib Receives Second Breakthrough Designation for NSCLC

Fineline Cube Aug 21, 2025

On August 20, 2025, Sino Biopharmaceutical Limited (HKG: 1177) announced that its selective HER2 tyrosine...

Company Deals Medical Device

Haohai Biotech Terminates OK Lens Distribution Deal with Brighten Optix Amid Carl Zeiss Acquisition

Fineline Cube Aug 21, 2025

Shanghai Haohai Biological Technology Co., Ltd. (HKG: 6826, SHA: 688366) announced the termination of its...

Company Deals

Nanjing Zenshine Pharma Partners with Cigalah Medpharm to Advance Sebaloxavir Marboxil in MENA

Fineline Cube Aug 21, 2025

On August 21, 2025, Nanjing Zenshine Pharmaceuticals Co., Ltd, a China-based developer of small molecule...

Policy / Regulatory

China Releases Draft Guidelines for Single-Arm Oncology Trials to Support Drug Approvals

Fineline Cube Aug 21, 2025

On August 20, 2025, the Center for Drug Evaluation (CDE) of the National Medical Products...

Posts pagination

1 … 137 138 139 … 691

Recent updates

  • Shanghai Stexo Biotechnology Secures NMPA Clinical Approval for STX11101 Extracellular Vesicle Therapy in Acute Liver Failure
  • Biocytogen and Whitehawk Forge Global BsADC Partnership to Accelerate Next-Generation Cancer Therapies
  • Sino Biopharmaceutical Expands GSK Partnership to Commercialize Trelegy and Anoro Ellipta in China
  • China Adds Methoxyethyl Etomidate, Loretomidate and Solriamfetol to Controlled Psychotropic Substances List
  • China NMPA Launches PIONEER Program to Accelerate NAMs Adoption in Drug Development
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Shanghai Stexo Biotechnology Secures NMPA Clinical Approval for STX11101 Extracellular Vesicle Therapy in Acute Liver Failure

Others

Biocytogen and Whitehawk Forge Global BsADC Partnership to Accelerate Next-Generation Cancer Therapies

Company Deals

Sino Biopharmaceutical Expands GSK Partnership to Commercialize Trelegy and Anoro Ellipta in China

Policy / Regulatory

China Adds Methoxyethyl Etomidate, Loretomidate and Solriamfetol to Controlled Psychotropic Substances List

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.